Clinical Trials Logo
  1. Home
  2. Hodgkin Lymphoma
  3. NCT04996862
  4. Details
NCT04996862 Clinical Trial

A Survey Exploring Health and Screening Tests in People Treated for Hodgkin Lymphoma

Hodgkin Lymphoma Clinical Trial

Official title:
A Study of Health Beliefs and Cancer Screening Behaviours and Intentions in Hodgkin Lymphoma Survivors

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04996862
Other study ID # CFTSp195
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2021
Est. completion date September 28, 2021

Study information
Verified date September 2021
Source The Christie NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A survey of health beliefs and cancer screening behaviour and intentions in Hodgkin lymphoma survivors

Description:

A survey of Hodgkin lymphoma survivors registered in a follow-up database, examining health beliefs (using Health Belief Model) around breast, bowel and lung cancer screening, previous screening uptake and future uptake intentions

Recruitment information / eligibility
Status Completed
Enrollment 165
Est. completion date September 28, 2021
Est. primary completion date September 28, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Details held in the ADAPT database at The Christie NHS Foundation trust - Aged 18-80 - Previously treated for Hodgkin lymphoma without evidence of relapse for at least 5 years - Treated with radiotherapy and/or alkylating agent containing chemotherapy Exclusion Criteria: * Have previously stated they do not wish to be contacted for research

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United Kingdom The Christie NHS Foundation Trust Manchester

Sponsors (1)
Lead Sponsor Collaborator
The Christie NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome
Type Measure Description Time frame Safety issue
Primary The psychosocial factors predictive of uptake of breast, bowel and lung cancer screening in HL survivors Questionnaires At baseline visit
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Active, not recruiting NCT03617666 - Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Recruiting NCT02507479 - Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies Phase 2
Active, not recruiting NCT02191930 - Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma Phase 2
Completed NCT01943682 - Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Phase 1
Completed NCT01393106 - Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma Phase 2
Terminated NCT00992030 - R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma Phase 3
Terminated NCT00722865 - Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma Phase 2
Unknown status NCT00598624 - Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Phase 2
Completed NCT03242902 - To Decrease Fatigue With Light Therapy Phase 3
Active, not recruiting NCT05205512 - Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial N/A
Recruiting NCT03681561 - Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT03250962 - SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma Phase 2
Recruiting NCT04510610 - Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Phase 2/Phase 3
Completed NCT06295211 - Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
Active, not recruiting NCT02256137 - A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
Completed NCT02432235 - Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma Phase 1